Overdose of Anticoagulant

For routine management of a patient on an anticoagulant — agent choice, duration, monitoring, procedures, restarting after a bleed — see VTE Treatment & Anticoagulation Management.

Risk assessment

History: time of last dose, dose taken, indication for the anticoagulant.

Risk factors for adverse events with dabigatran: age > 75, low body weight (< 50kg), moderate-severe renal impairment (CrCl < 50mL/min).

Severity grading:

• Mild: local soft tissue haematomas or bleeding from minor wounds to non-life-threatening regions.
• Moderate-severe: Hb drop of 20g/L; transfusion of 2 units RBCs; bleeding into a critical region (intraocular, intracranial, intrapulmonary, pericardial, GI tract, retroperitoneum, peri/intraspinal, major muscle group with compartment syndrome risk).
• Life-threatening: uncontrolled progression of the above with worsening symptoms; Hb drop of 50g/L; transfusion of 4 units RBCs; circulatory shock; bleeding requiring surgical intervention.

Always factor in comorbidities and other situational context alongside these thresholds. These bands mirror the ISTH major-bleeding definition — a haemoglobin drop of at least 20g/L or transfusion of at least 2 units of blood — used to standardise reporting of anticoagulant-related bleeding in the literature this page draws on.

Investigations

In a patient with clinically relevant bleeding: FBC (Hb, platelets); coagulation profile — INR (unreliable for dabigatran), APTT (crude, but a normal APTT makes clinically significant dabigatran-related bleeding unlikely — still worth doing, as other contributors to a bleeding diathesis may be present), TCT (dilute thrombin clotting time, e.g. HEMOCLOT — the most sensitive test for quantifying dabigatran effect); UEC, glucose, calcium; group and hold or crossmatch as clinically indicated.

Management

Reversal should be reserved for life-threatening, uncontrolled, or critical-site bleeding, or when an urgent procedure is required — the thromboembolic risk of reversal has to be weighed against the bleeding risk.

• Stop the anticoagulant (and any antiplatelet agent).
• Assess severity (mild bleeding may just need a skipped dose).
• Control the source of haemorrhage; haemodynamic stabilisation and transfusion support as needed.
• Coagulation screen (APTT, TT).
• Check time of last dose and discuss with haematology.
• Correct any coexisting bleeding diathesis — e.g. platelets if < 80.
• Activated charcoal for most NOACs if ingested within 2-4 hours. For dabigatran specifically, give idarucizumab (Praxbind) 5g IV (two separate 2.5g boluses) — a specific reversal agent that rapidly neutralises its effect.
• If actively bleeding: tranexamic acid 1g IV stat, then 1g infusion over 8 hours.
• For factor Xa inhibitors (apixaban, rivaroxaban): consider FFP, Prothrombinex 25-50 IU/kg, or FVIIa (eptacog) 100mcg/kg.
• Haemodialysis (particularly in renal failure) removes ~60% of dabigatran over 2-3 hours.
• Fondaparinux has no specific antidote; management is supportive (recombinant FVIIa may be considered in life-threatening bleeding, despite limited evidence).

Warfarin overdose, no therapeutic need for warfarin (e.g. took someone else’s dose, or pregnant/anticoagulated with an isolated accidental dose): vitamin K 5mg PO or IV daily for 2 days; recheck INR in 48 hours.

Warfarin overdose, therapeutic need for warfarin: monitor INR every 6 hours; give vitamin K 0.5–2mg IV if INR > 5, repeating doses if it remains elevated; if INR falls below 2, start heparin if there’s an absolute indication for anticoagulation. Warfarin toxicity is generally defined as INR > 3.0 (> 3.5 with a mechanical heart valve); coagulopathy as INR > 1.4. For life-threatening bleeding on a vitamin K antagonist: IV vitamin K plus 4-factor prothrombin complex concentrate — faster and more reliable than FFP, which is only a fallback when PCC is unavailable.

Long-acting anticoagulant rodenticide (“superwarfarin”) ingestion: superwarfarins are roughly 100x more potent than warfarin. Very large doses of oral vitamin K are needed for weeks to months once anticoagulation occurs. Close initial INR monitoring establishes the correct dose. Active bleeding or high bleeding risk (INR > 9) needs immediate reversal with prothrombin complex concentrate and FFP, in addition to vitamin K.